
    
      This is a phase I, open-label, randomized study in healthy adults. Eligible subjects will be
      given single dose of either Dry Powdered Measles Vaccine (PMV) by PuffhalerÂ® device, Dry PMV
      by SoloventTM device or licensed measles vaccine by subcutaneous route (SMV). Solicited
      reactions will be assessed for first 14 days after vaccination and unsolicited adverse events
      will be assessed till 84 days after vaccination. Subjects will be followed for 180 days for
      any SAEs.
    
  